FGFR4-IN-1 significantly inhibits the proliferation of HuH-7 hepatocellular carcinoma cells with IC50 of 7.8 nM. FGFR4 may be a novel therapeutic target for gastric cancer.
|Cell lines||HuH-7 hepatocellular carcinoma cells|
|Preparation method||FGFR4-IN-1 is dissolved in DMSO. Methylene blue staining proliferation assay (MBS): The effect of compounds on cell proliferation is assessed using HuH-7 hepatocellular carcinoma cells are cultured in the vendor-recommended medium, 10% foetal calf serum, 1 mM sodium pyruvate, 1x Penicillin/Streptomycin at 37°C in a humidified 5% CO2 incubator. Specifically, 5000 cells/well are seeded in 96-well tissue culture plates in a total media volume of 100 μL/well and increasing compound dilutions or DMSO are added 24 hours thereafter in triplicates. 72 hours after compound addition, cells are fixed by adding 25 and incubated for 10 minutes at room temperature. Cells are washed three times with H2O. Cells are washed 3 times with H2O, 200 mL/well and then lysed by adding 200 mL/well of 3% HCl for 30 minutes at room temperature with shaking. Optical density is measured at A650 nm. The concentration of compound providing 50% of proliferation inhibition with respect to DMSO-treated cells is determined (IC50) using XLFit software.|
|Incubation time||72 hours|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO: 5 mg/mL (Need warming)|
|Related FGFR Products|
Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).
WAY-625530 is a Fibroblast Growth Factor Receptor 1 Kinase inhibitor.
WAY-621856 is a FGFR inhibitor.
WAY-603814 is a FGFR1 inhibitor
WAY-600868 is a FGFR3 inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.